[go: up one dir, main page]

NO971764D0 - Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse - Google Patents

Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse

Info

Publication number
NO971764D0
NO971764D0 NO971764A NO971764A NO971764D0 NO 971764 D0 NO971764 D0 NO 971764D0 NO 971764 A NO971764 A NO 971764A NO 971764 A NO971764 A NO 971764A NO 971764 D0 NO971764 D0 NO 971764D0
Authority
NO
Norway
Prior art keywords
viable
pollution
preparation
adenoviruses
free
Prior art date
Application number
NO971764A
Other languages
English (en)
Other versions
NO320090B1 (no
NO971764L (no
Inventor
Patrice Yeh
Michel Perricaudet
Cecile Orsini
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO971764D0 publication Critical patent/NO971764D0/no
Publication of NO971764L publication Critical patent/NO971764L/no
Publication of NO320090B1 publication Critical patent/NO320090B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A61L2103/05—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19971764A 1994-10-28 1997-04-17 Rekombinant adenovirus, dens fremstilling samt farmasoytisk preparat inneholdende virusen. NO320090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413355A FR2726285B1 (fr) 1994-10-28 1994-10-28 Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
PCT/FR1995/001415 WO1996013596A1 (fr) 1994-10-28 1995-10-25 Adenovirus depourvus de particules contaminantes viables, preparation et utilisations

Publications (3)

Publication Number Publication Date
NO971764D0 true NO971764D0 (no) 1997-04-17
NO971764L NO971764L (no) 1997-04-17
NO320090B1 NO320090B1 (no) 2005-10-24

Family

ID=9468601

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971764A NO320090B1 (no) 1994-10-28 1997-04-17 Rekombinant adenovirus, dens fremstilling samt farmasoytisk preparat inneholdende virusen.

Country Status (13)

Country Link
US (2) US6312946B1 (no)
EP (1) EP0787199A1 (no)
JP (1) JPH10507922A (no)
KR (1) KR100424803B1 (no)
CN (1) CN1110564C (no)
AU (1) AU703539B2 (no)
FI (1) FI971783L (no)
FR (1) FR2726285B1 (no)
IL (1) IL115779A0 (no)
MX (1) MX9702553A (no)
NO (1) NO320090B1 (no)
WO (1) WO1996013596A1 (no)
ZA (1) ZA959086B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
JP3565859B2 (ja) * 1994-10-28 2004-09-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改良されたアデノウイルスおよびその使用法
JPH10510987A (ja) * 1994-12-12 1998-10-27 ジェネティック セラピー，インコーポレイテッド 改良アデノウイルスベクターおよび生産者細胞
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
US6730662B1 (en) 1996-07-05 2004-05-04 Mcgill University Adenovirus E4 proteins for inducing cell death
AU731924B2 (en) * 1996-07-05 2001-04-05 Philip E. Branton Adenovirus E4 proteins for inducing cell death
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
KR20010020342A (ko) 1997-04-28 2001-03-15 자끄 사비나 종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
PT974668E (pt) 1998-07-07 2003-01-31 Transgene Sa Utilizacao de blocos de leitura da regiao e4 adenoviral para melhorar a expressao de um gene relevante
US6461869B1 (en) * 1999-07-20 2002-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Purging leukemia cells from hematopoietic stem cells
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
WO2001090392A1 (en) * 2000-05-26 2001-11-29 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US20080193484A1 (en) * 2004-10-25 2008-08-14 Biogen Idec Ma Inc. Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations
AU2007276793B2 (en) * 2006-07-28 2014-01-16 Sanofi Composition and method for treatment of tumors
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP2606137B1 (en) 2010-08-16 2018-08-01 Salk Institute For Biological Studies Anti-cancer adenoviruses
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
CN108064275A (zh) 2014-09-24 2018-05-22 萨克生物研究学院 溶瘤肿瘤病毒及使用方法
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
IL315224A (en) 2017-05-08 2024-10-01 Gritstone Bio Inc Neoantigen alphavirus vectors
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
IL288283B2 (en) 2019-05-30 2025-05-01 Gritstone Bio Inc Modified adenovirus
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN116802280B (zh) * 2021-01-21 2024-09-17 希力德株式会社 不包括有复制能力的腺病毒的新型腺病毒载体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy

Also Published As

Publication number Publication date
FR2726285B1 (fr) 1996-11-29
KR970707292A (ko) 1997-12-01
EP0787199A1 (fr) 1997-08-06
JPH10507922A (ja) 1998-08-04
NO320090B1 (no) 2005-10-24
IL115779A0 (en) 1996-01-19
WO1996013596A1 (fr) 1996-05-09
FR2726285A1 (fr) 1996-05-03
AU703539B2 (en) 1999-03-25
MX9702553A (es) 1997-06-28
ZA959086B (en) 1996-07-16
NO971764L (no) 1997-04-17
FI971783A0 (fi) 1997-04-25
US6312946B1 (en) 2001-11-06
FI971783A7 (fi) 1997-04-25
US20010039046A1 (en) 2001-11-08
KR100424803B1 (ko) 2004-06-12
FI971783L (fi) 1997-04-25
US6482617B2 (en) 2002-11-19
AU3847795A (en) 1996-05-23
CN1110564C (zh) 2003-06-04
CN1162338A (zh) 1997-10-15

Similar Documents

Publication Publication Date Title
NO971764L (no) Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse
NO954369D0 (no) Oksazolidindionderivater, deres fremstilling og anvendelse
NO933434D0 (no) Piperidinderivater, deres fremstilling og anvendelse
NO912058L (no) Bioforlikelige membraner, deres fremstilling og anvendelse
DK374389D0 (da) Arylbenzenoxazolidinoner, deres fremstilling og anvendelse
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
NO964306D0 (no) Ligninblanding, fremstilling og anvendelse derav
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
NO951447D0 (no) Organoaluminoksyprodukt, fremstilling og anvendelse
NO953673L (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
DK388989A (da) Acylcyanoguanidiner, deres fremstilling og anvendelse
DK0690065T3 (da) Biphenyl-2,2'-diyl-bis-diphenylphosphiner, deres fremstilling og deres anvendelse
DK435289A (da) Piperazindioner, deres fremstilling og anvendelse
NO951418D0 (no) Peptidderivater, deres fremstilling og anvendelse som terapeutika
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
NO933435D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DK73091D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
DK225089A (da) 2-adamantyl-4-isothiazolin-3-oner, deres fremstilling og anvendelse
NO179073C (no) Imid-terminerte polynitrogenforbindelser, deres fremstilling og anvendelse
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
FI965172L (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse
NO951812D0 (no) Pyrrolderivater, deres fremstilling og anvendelse
DK592389A (da) Penemderivater, deres fremstilling og anvendelse